News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,615 Results
Type
Article (41917)
Company Profile (333)
Press Release (665365)
Section
Business (210166)
Career Advice (2080)
Deals (36583)
Drug Delivery (100)
Drug Development (82854)
Employer Resources (171)
FDA (16491)
Job Trends (15360)
News (355493)
Policy (33832)
Tag
Academia (2574)
Alliances (51188)
Alzheimer's disease (1280)
Approvals (16452)
Artificial intelligence (158)
Bankruptcy (362)
Best Places to Work (11716)
Biotechnology (215)
Breast cancer (193)
Cancer (1402)
Cardiovascular disease (116)
Career advice (1741)
Cell therapy (286)
Clinical research (66252)
Collaboration (498)
Compensation (267)
COVID-19 (2613)
C-suite (111)
Data (1406)
Diabetes (179)
Diagnostics (6255)
Earnings (86580)
Employer resources (149)
Events (112879)
Executive appointments (405)
FDA (17190)
Funding (439)
Gene therapy (206)
GLP-1 (633)
Government (4453)
Healthcare (18879)
Infectious disease (2706)
Inflammatory bowel disease (115)
Interviews (320)
IPO (16623)
Job creations (4052)
Job search strategy (1488)
Layoffs (439)
Legal (8329)
Lung cancer (200)
Lymphoma (100)
Manufacturing (216)
Medical device (13300)
Medtech (13305)
Mergers & acquisitions (20122)
Metabolic disorders (479)
Neuroscience (1614)
NextGen Class of 2024 (6625)
Non-profit (4515)
Northern California (1711)
Obesity (272)
Opinion (207)
Patents (124)
People (58425)
Phase I (20521)
Phase II (29150)
Phase III (21860)
Pipeline (517)
Postmarket research (2651)
Preclinical (8730)
Radiopharmaceuticals (241)
Rare diseases (276)
Real estate (6241)
Regulatory (22529)
Research institute (2359)
Resumes & cover letters (358)
Southern California (1479)
Startups (3712)
United States (15446)
Vaccines (583)
Weight loss (197)
Date
Today (2)
Last 7 days (256)
Last 30 days (2163)
Last 365 days (35785)
2024 (35717)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54794)
2019 (47400)
2018 (35771)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (203)
Asia (40154)
Australia (6423)
California (3863)
Canada (1467)
China (317)
Colorado (176)
Connecticut (181)
Europe (85490)
Florida (540)
Georgia (136)
Illinois (397)
Indiana (233)
Maryland (642)
Massachusetts (3025)
Michigan (177)
Minnesota (293)
New Jersey (1125)
New York (1100)
North Carolina (761)
Northern California (1711)
Ohio (146)
Pennsylvania (936)
South America (1158)
Southern California (1479)
Texas (565)
Utah (109)
Washington State (408)
707,615 Results for "tolmar pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care
Tolmar Inc., a fully integrated pharmaceutical company, announced results from a landmark survey of more than 300 US physicians, revealing barriers to treatment with testosterone-replacement therapy among patients and physicians that, if addressed, may improve patient care.
June 2, 2024
·
7 min read
News
The pharma& Group Enters into an Exclusive Promotional Agreement with Tolmar, Inc. to Promote Rubraca® (rucaparib) in the U.S. for the Treatment of Metastatic Castration-Resistant Prostate Cancer
September 24, 2024
·
8 min read
BioMidwest
Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder
Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ) announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets).
October 18, 2022
·
4 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Business
Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®- Tolmar’s 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists -
Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote ALKINDI SPRINKLE®.
November 15, 2021
·
10 min read
Press Releases
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
December 3, 2024
·
2 min read
Press Releases
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq
November 28, 2024
·
3 min read
Press Releases
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
December 11, 2024
·
3 min read
Press Releases
Bexion Pharmaceuticals, Inc. to Participate in the Jefferies London Healthcare Conference
November 12, 2024
·
2 min read
BioMidwest
Nika Pharmaceuticals, Inc. (NIKA) Presents Its Business Strategy
Nika Pharmaceuticals, Inc. introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders.
June 3, 2024
·
5 min read
1 of 70,762
Next
